MX393649B - Vacunas y anticuerpos contra el dengue - Google Patents

Vacunas y anticuerpos contra el dengue

Info

Publication number
MX393649B
MX393649B MX2017001017A MX2017001017A MX393649B MX 393649 B MX393649 B MX 393649B MX 2017001017 A MX2017001017 A MX 2017001017A MX 2017001017 A MX2017001017 A MX 2017001017A MX 393649 B MX393649 B MX 393649B
Authority
MX
Mexico
Prior art keywords
dimer
denv
ede
envelope
dengue virus
Prior art date
Application number
MX2017001017A
Other languages
English (en)
Other versions
MX2017001017A (es
Inventor
Alexander Rouvinski
Felix Augusto Rey
Gavin Screaton
Giovanna Barba-Spaeth
Juthathip Mongkolsapaya
Marie- Christine Vaney
Pablo Guardado-Calvo
Stéphane Duquerroy
Original Assignee
Imperial College Sci Tech & Medicine
Pasteur Institut
Univ Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Sci Tech & Medicine, Pasteur Institut, Univ Paris Sud filed Critical Imperial College Sci Tech & Medicine
Publication of MX2017001017A publication Critical patent/MX2017001017A/es
Publication of MX393649B publication Critical patent/MX393649B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un epítopo del dímero de envoltura (EDE) del virus del dengue, en donde el EDE:c) abarca los polipéptidos de un dímero del polipéptido de envoltura del virus del dengue; y/od) se presenta en un dímero de las proteínas de envoltura; y/oc) se forma de residuos consecutivos o no consecutivos del dímero del polipéptido de envoltura,en donde el dímero es un homodímero o un heterodímero de polipéptidos de envoltura nativos y/o mutantes, de cualquiera de uno o dos de DENV-1, DENV-2, DENV-3 y DENV-4. El EDE puede ser un dímero estabilizado del ectodominio de la glucoproteína E de envoltura del virus del dengue recombinante (sE), en donde el dímero:se estabiliza de manera covalente con al menos un puente de disulfuro intercatenario entre los dos monómeros de sE, y/o se estabiliza de manera covalente con al menos un reticulador que reacciona con sulfhidrilo entre dos monómeros de sE, y/ose estabiliza de manera covalente mediante la unión de dos monómeros de sE a través de azúcares modificados; y/ose estabiliza de manera covalente mediante la formación como una cadena de polipéptidos simple, opcionalmente con una región ligadora, opcionalmente una región ligadora rica en glicina-serina, que separa las secuencias de sE, y/ose estabiliza de manera no covalente mediante la sustitución de al menos un residuo de aminoácido en la secuencia de aminoácidos de al menos un monómero de sE con al menos un aminoácido de la cadena lateral voluminosa, en la interfaz dimérica o en el ligador de dominio 1 (D1) / dominio 3 (D3) de cada monómero.Un compuesto, por ejemplo, un anticuerpo o un fragmento de anticuerpo que puede neutralizar más de un serotipo del virus del dengue, por ejemplo, un anticuerpo que se puede fijar a un EDE de la invención.
MX2017001017A 2014-07-23 2015-07-23 Vacunas y anticuerpos contra el dengue MX393649B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1413086.8A GB201413086D0 (en) 2014-07-23 2014-07-23 Methods
PCT/GB2015/052139 WO2016012800A1 (en) 2014-07-23 2015-07-23 Anti-dengue vaccines and antibodies

Publications (2)

Publication Number Publication Date
MX2017001017A MX2017001017A (es) 2017-08-10
MX393649B true MX393649B (es) 2025-03-21

Family

ID=51495027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001017A MX393649B (es) 2014-07-23 2015-07-23 Vacunas y anticuerpos contra el dengue

Country Status (7)

Country Link
US (3) US11198706B2 (es)
EP (3) EP3172229B1 (es)
JP (3) JP7433744B2 (es)
CA (1) CA2988499A1 (es)
GB (1) GB201413086D0 (es)
MX (1) MX393649B (es)
WO (1) WO2016012800A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3359652A1 (en) * 2015-10-07 2018-08-15 The University of North Carolina at Chapel Hill Methods and compositions for dengue virus vaccines and diagnostistics
WO2017142831A1 (en) * 2016-02-16 2017-08-24 Albert Einstein College Of Medicine, Inc. Dengue virus glycoprotein e diii variants and uses thereof
GB2550418A (en) 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
MX374731B (es) 2016-06-06 2025-03-06 Univ Wien Med Método para la detección de un anticuerpo igm específico para un flavivirus en una muestra.
GB201610162D0 (en) * 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2020500007A (ja) 2016-10-13 2020-01-09 マサチューセッツ インスティテュート オブ テクノロジー ジカウイルスエンベロープタンパク質に結合する抗体およびその使用
US20190358313A1 (en) * 2016-12-23 2019-11-28 Expres2Ion Biotechnologies Aps New flavivirus vaccine
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EP4477230A3 (en) * 2019-08-06 2025-05-14 The University of North Carolina at Chapel Hill Methods and compositions for stabilized recombinant flavivirus e protein dimers
US20250188154A1 (en) * 2020-09-15 2025-06-12 Duke University Coronavirus antibodies and uses thereof
GB2603567B (en) * 2021-02-03 2024-11-20 D Silver Joshua Viral load tester and applications thereof
WO2025101126A1 (en) * 2023-11-06 2025-05-15 Agency For Science, Technology And Research Modified flavivirus polypeptide and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006068A2 (en) * 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
CA2441986A1 (en) 2001-03-27 2002-10-03 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
JP4990621B2 (ja) * 2003-07-02 2012-08-01 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａプロセシングタンパク質複合体及びその使用
CA2894300A1 (en) * 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
CA2567741A1 (en) 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
EP1948688A2 (en) 2005-11-14 2008-07-30 Psma Development Company, L.L.C. Compositions of and methods of using stabilized psma dimers
DK2257624T5 (da) 2008-02-05 2012-09-10 Medical Res Council Fremgangsmåder og sammensætninger
US7923016B2 (en) 2008-02-27 2011-04-12 Medical College Of Wisconsin Engineered CXCL12 α locked dimer polypeptide
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
KR20130138789A (ko) * 2010-10-29 2013-12-19 머크 샤프 앤드 돔 코포레이션 재조합 서브유닛 뎅기 바이러스 백신
EP2834265A4 (en) * 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
US9267114B2 (en) 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods

Also Published As

Publication number Publication date
JP2017529096A (ja) 2017-10-05
JP7433744B2 (ja) 2024-02-20
WO2016012800A1 (en) 2016-01-28
US20260055145A1 (en) 2026-02-26
JP2024037829A (ja) 2024-03-19
EP3172229A1 (en) 2017-05-31
US20180037611A1 (en) 2018-02-08
US11198706B2 (en) 2021-12-14
EP4282483A3 (en) 2024-09-11
US12415836B2 (en) 2025-09-16
EP4282483A2 (en) 2023-11-29
US20220127307A1 (en) 2022-04-28
JP2025172747A (ja) 2025-11-26
CA2988499A1 (en) 2016-01-28
BR112017001340A2 (pt) 2017-11-14
EP4223773A2 (en) 2023-08-09
MX2017001017A (es) 2017-08-10
EP3172229B1 (en) 2023-05-10
EP4223773A3 (en) 2023-12-06
GB201413086D0 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
MX393649B (es) Vacunas y anticuerpos contra el dengue
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
AR094149A1 (es) Proteinas multifuncion que comprenden chm de clase i multivalente unido mediante disulfuro
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
MX2016008539A (es) Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas.
BR112018075396A2 (pt) anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
CO2017004318A2 (es) Variantes de interferon α2b
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
EA201400046A1 (ru) Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
UA108778C2 (xx) Протираковий злитий протеїн
EA201691780A1 (ru) Наноструктурированный песок, способ получения наноструктурированного песка, способ разделения смеси загрязняющее вещество-вода с помощью наноструктурированного песка и дополнительные применения
EA201991918A1 (ru) Самосборные белковые наночастицы со встроенными белками с шестиспиральным пучком
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
EA202190264A1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
AR116876A1 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
EA201691589A1 (ru) Стабилизированные основанные на фибронектине каркасные молекулы
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
GB2543713A (en) Polymeric proteins and uses thereof
MX2022000778A (es) Proteina quimerica l1 del virus de papiloma humano.
JP2018508571A5 (es)

Legal Events

Date Code Title Description
HH Correction or change in general